Greenland Mines Ltd (NASDAQ: GRML) has announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. The company also confirmed that Nasdaq has formally approved its application relating to the March 2026 transaction, resolving prior deficiencies and bringing the company into full compliance with listing requirements.
The strategic shift follows the completion of the acquisition of the Sarfartoq project on Sept. 1, after receiving approval from the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. According to the company, planned annual neodymium-praseodymium (NdPr) oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years.
This development underscores the growing importance of rare earth elements, particularly NdPr, which are critical for permanent magnets used in electric vehicles, wind turbines, and other clean energy technologies. By advancing the Sarfartoq project, Greenland Mines is positioning itself to play a significant role in diversifying the global supply chain for these essential materials, which are currently dominated by China.
The company is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining. Hawkins brings extensive experience in capital markets and strategic development, which will be valuable as Greenland Mines advances both the Sarfartoq and Skaergaard projects. The Skaergaard project, located in southeast Greenland, hosts palladium, gold, and platinum resources, adding to the company's portfolio of critical and precious metals.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, is a strategic move to unlock shareholder value and allow each business to focus on its core operations. The mining division will concentrate on rare earths and critical minerals, while the biotech division can pursue its pharmaceutical development with more focused management and capital allocation.
The Nasdaq approval and compliance resolution remove a potential overhang on the stock, providing clarity for investors. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. Additionally, the broader North Atlantic Critical Metals Corridor vision aims to link Greenland resources with allied downstream jurisdictions and industrial infrastructure, enhancing supply chain security for Western nations.
With the Sarfartoq acquisition completed and the Initial Assessment showing robust economics, Greenland Mines is poised to become a key player in the critical minerals sector. The company's focus on NdPr production aligns with global efforts to reduce reliance on Chinese rare earth processing. As the demand for clean energy technologies grows, the importance of projects like Sarfartoq cannot be overstated.
The company's progress is noteworthy, but investors should conduct their own due diligence. For more information on Greenland Mines, visit the company's newsroom at https://ibn.fm/GRML.
